TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590173
Drug: COH for IVF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
Study: NCT01527994
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral pill- inactive compound
Study: NCT02203643
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03553238
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
Study: NCT01067430
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet, 90 mg taken once a day for 14 days
Study: NCT01067430
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enteric coated tablet 50 mg given three times a day for 14 days
Study: NCT02107885
Drug: DS-1971
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 subjects in each group will receive DS-1971.
Study: NCT02107885
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 subjects in each group will receive placebo.
Study: NCT00674921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch, magnesium stearate, sodium lauryl sulphate
Study: NCT00913822
Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
Normalized name: desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02182518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during run-in period
Study: NCT01599884
Drug: Oral acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Identical placebo pills twice daily for 8 weeks
Study: NCT03705234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT01599286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
Study: NCT02701673
Drug: Caphosol
Normalized name: Caphosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study: NCT02701673
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
Study: NCT00003287
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003287
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003287
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03399448
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Study: NCT00772759
Drug: AZD3199 Turbuhaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
Study: NCT00772759
Drug: Placebo Turbuhaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple (o.d. for 12 days)
Study: NCT01276704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains same filler materials as commercially available Brevail® but without active SDG.
Study: NCT02235324
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02235324
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06278493
Drug: AL2846 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi -target receptor tyrosine kinase inhibitor.
Study: NCT00481936
Drug: VB6-845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion once weekly for 4 weeks
Study: NCT02769793
Drug: Levodopa dispersible
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Study: NCT02769793
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Study: NCT04246060
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT
Study: NCT00319917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01829516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo
Study: NCT02862574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection once weekly
Study: NCT02862574
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally weekly as part of the participant's current treatment regimen
Study: NCT02862574
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Study: NCT02749747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg placebo once a day use for 60 days
Study: NCT04870866
Drug: Nicotinamide ribonucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two year intervention
Study: NCT03733327
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT02012517
Drug: Prolonged antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01421056
Drug: CHF 5074 2x
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
Study: NCT01822925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
Study: NCT01517984
Drug: Standard Immunosuppressive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Study: NCT02243358
Drug: Folfox6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03070678
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT05456048
Drug: VAH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study: NCT05456048
Drug: VEN+HMA regimen
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study: NCT03808935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
Study: NCT01323608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00132730
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00320606
Drug: Immunosuppression Withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
Study: NCT00123565
Drug: Hexadecasaccharide (SR123781A)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical end formulation buffer
Study: NCT00718315
Drug: erythromycin [Eritex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical, daily for 30 days.
Study: NCT00718315
Drug: Fisiogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical, daily for 30 days
Study: NCT02906111
Drug: estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse
Study: NCT03825705
Drug: TQB2450 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT03132142
Drug: Vehicle patch
Normalized name: EXYDERM Transdermal Vehicle Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Study: NCT00399529
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
Study: NCT00223951
Drug: R89674 (generic name not yet established)
Normalized name: forget-me-not extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518479
Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172014
Drug: midazolam and fentanyl citrate infusion
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Study: NCT04435158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection
Study: NCT01798602
Drug: Rosuvastatin or identical placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet crushed for administration via feeding tube
Study: NCT01798602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo for rosuvastatin
Study: NCT00454116
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02466828
Drug: Feraheme®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
Study: NCT00093509
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
Study: NCT02468583
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT02468583
Drug: TCA IR 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator
Study: NCT00863161
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, oral, single dose
Study: NCT03763630
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered in same frequency and manner as intervention
Study: NCT01493414
Drug: INC424
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Study: NCT03739528
Drug: Tobramycin + Dexamethasone
Normalized name: dexamethasone / tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Study: NCT03782415
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
Study: NCT00579644
Drug: Combination of Minocycline and MTX or MTX alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg
Study: NCT00579644
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study.
Study: NCT02249078
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 solution for injection
Study: NCT02249078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2-mL vial solution for injection
Study: NCT02957630
Drug: 15 mg E4/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study: NCT02957630
Drug: 30 mcg EE/150 mcg LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study: NCT02957630
Drug: 20 mcg EE/3 mg DRSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Study: NCT01108601
Drug: Ringer's Lactate (0.03% Ciprofloxacin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
Study: NCT03528902
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02935322
Drug: 0.2 % NaF mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period.
Study: NCT04162834
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Study: NCT02690142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose i.v.
Study: NCT02690142
Drug: ABY-035 i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose i.v.
Study: NCT02690142
Drug: ABY-035 s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose s.c.
Study: NCT04309643
Drug: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
Study: NCT01731925
Drug: Placebo (for sunitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00940602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
Study: NCT01854528
Drug: ABT-450/r/ABT-267, ABT-333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT00001561
Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH
Normalized name: vaccinia immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01474109
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo once daily
Study: NCT00862940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets twice daily
Study: NCT04445948
Drug: Clarithromycin 500 milligrams Tablets
Normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Macrolide antibiotic
Study: NCT03732469
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
Study: NCT03732469
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
Study: NCT02434861
Drug: Cooperstown Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
Study: NCT02181920
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02181920
Drug: Diclofenac placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003525
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02476448
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used to distend the bladder for cystoscopic evaluation
Study: NCT02476448
Drug: Dextrose 10%
Normalized name: DEXTROSE 10% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used to distend the bladder for cystoscopic evaluation
Study: NCT03688971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT00451230
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05231863
Drug: TKIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: tyrosine kinase inhibitors based therapy
Study: NCT00887354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly: Administered orally~Daily: Administered subcutaneously
Study: NCT02784340
Drug: Bupivicaine and Fentany
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005979
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no